Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Details)

v3.7.0.1
Discontinued Operations (Details) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]      
Accounts and other receivables $ 0   $ 1,598,994
Inventory, net 0   1,374,618
Prepaid expenses 0   170,635
Assets associated with discontinued operations, current 0   3,144,247
Property and equipment, net of accumulated depreciation 0   70,973
Patents and trademarks, net of accumulated amortization 0   34,282
Assets associated with discontinued operations, noncurrent 0   105,255
Total assets associated with discontinued operations 0   3,249,502
Accounts payable 152,108   1,957,938
Accrued liabilities 3,402,212   607,659
Deferred revenue 0   2,300,000
Liabilities associated with discontinued operations, current 3,554,320   $ 4,865,597
Revenue:      
Lymphoseek sales revenue 2,917,213 $ 3,773,880  
Grant and other revenue 0 190  
Total revenue 2,917,213 3,774,070  
Cost of goods sold 364,192 533,440  
Gross profit 2,553,021 3,240,630  
Operating expenses:      
Research and development 283,533 587,249  
Selling, general and administrative 820,203 1,463,534  
Total operating expenses 1,103,736 2,050,783  
Income from discontinued operations 1,449,285 1,189,847  
Interest expense (1,718,506) (2,194,280)  
Loss before income taxes (269,221) (1,004,433)  
Benefit from income taxes 13,360 0  
Loss from discontinued operations $ (255,861) $ (1,004,433)